Proteomics approach to identify biomarkers for upper gastrointestinal cancer

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.
   PubMed Web of Science ®Google Scholar
• Wasinger VC, Cordwell SJ, Cerpa-Poljak A, et al. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis. 1995;16:1090–1094.
   PubMed Web of Science ®Google Scholar
• Ebert MP, Rocken C. Molecular screening of gastric cancer by proteome analysis. Eur J Gastroenterol Hepatol. 2006;18:847–853.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697.
   PubMed Web of Science ®Google Scholar
• Wu C, Luo Z, Chen X, et al. Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers. Oncol Rep. 2009;21:1429–1437.
   PubMed Web of Science ®Google Scholar
• Wu W, Juan WC, Liang CR, et al. S100A9, GIF and AAT as potential combinatorial biomarkers in gastric cancer diagnosis and prognosis. Proteomics Clin Appl. 2012;6:152–162.
   PubMed Web of Science ®Google Scholar
• Li X, Gong Y, Wang Y, et al. Comparison of alternative analytical techniques for the characterisation of the human serum proteome in HUPO plasma proteome project. Proteomics. 2005;5:3423–3441.
   PubMed Web of Science ®Google Scholar
• Tseng CW, Yang JC, Chen CN, et al. Identification of 14-3-3β in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker. Proteomics. 2011;11:2423–2439.
   PubMed Web of Science ®Google Scholar
• Weiss W, Gorg A. Sample solublization buffers for two-dimensional electrophoresis. Methods Mol Biol. 2008;424:35–42.
   PubMedGoogle Scholar
• Tonge R, Shaw J, Middleton B, et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics. 2001;1:377–396.
   PubMed Web of Science ®Google Scholar
• Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16:1–27.
   PubMed Web of Science ®Google Scholar
• Qiu FM, Yu JK, Chen YD, et al. Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. J Exp Clin Cancer Res. 2009;28:126.
   PubMed Web of Science ®Google Scholar
• Umemura H, Togawa A, Sogawa K, et al. Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis. J Gastroenterol. 2011;46:577–585.
   PubMed Web of Science ®Google Scholar
• Liu W, Gao X, Cai Q, et al. Identification of novel serum biomarkers for gastric cancer by magnetic bead. Front Biosci. 2010;2:961–971.
   Google Scholar
• Yang J, Xiong X, Wang X, et al. Identification of peptide regions of SERPINA1 and ENOSF1 and their protein expression as potential serum biomarkers for gastric cancer. Tumour Biol. 2015;36:5109–5118.
   PubMed Web of Science ®Google Scholar
• Chong PK, Lee H, Loh MC, et al. Upregulation of plasma C9 protein in gastric cancer patients. Proteomics. 2010;10:3210–3221.
   PubMed Web of Science ®Google Scholar
• Fan NJ, Li K, Liu QY, et al. Identification of tubulin beta chain, thymosin beta-4-like protein 3, and cytochrome b-c(1) complex subunit 1 as serological diagnostic biomarkers of gastric cancer. Clin Biochem. 2013;46:1578–1584.
   PubMed Web of Science ®Google Scholar
• Uen YH, Lin KY, Sun DP, et al. Comparative proteomics, network analysis and post-translational modification identification reveal differential profiles of plasma Con A-bound glycoprotein biomarkers in gastric cancer. J Proteomics. 2013;83:197–213.
   PubMed Web of Science ®Google Scholar
• Ahn HS, Shin YS, Park PJ, et al. Serum biomarker panels for the diagnosis of gastric adenocarcinoma. Br J Cancer. 2012;106:733–739.
   PubMed Web of Science ®Google Scholar
• Bagaria B, Sood S, Sharma R, et al. Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis). Cancer Biol Med. 2013;10:148–157.
   PubMedGoogle Scholar
• Mealy K, Feely J, Reid I, et al. Tumour marker detection in oesophageal carcinoma. Eur J Surg Oncol. 1996;22:505–507.
   PubMed Web of Science ®Google Scholar
• Yi Y, Li B, Wang Z, et al. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Biomarkers. 2009;14:480–485.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Oka M, Hayashi H, et al. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer. 1997;79:1647–1655.
   PubMed Web of Science ®Google Scholar
• Chen W, Abnet CC, Wei WQ, et al. Serum markers as predictors of esophageal squamous dysplasia and early cancer. Anticancer Res. 2004;24:3245–3249.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xv Z, Wu X, et al. Potential diagnostic value of serum p53 antibody for detecting esophageal cancer: a meta-analysis. PLoS One. 2012;7:e52896.
   PubMed Web of Science ®Google Scholar
• Schwacke J, Millar TP, Hammond CE, et al. Discrimination of normal and esophageal cancer plasma proteomes by MALDI-TOF mass spectrometry. Dig Dis Sci. 2015;60:1645–1654.
   PubMed Web of Science ®Google Scholar
• Song E, Zhu R, Hammoud ZT, et al. LC-MS/MS quantitation of esophagus disease blood serum glycoproteins by enrichment with hydrazide chemistry and lectin affinity chromatography. J Proteome Res. 2014;13:4808–4820.
   PubMed Web of Science ®Google Scholar
• Zaidi AH, Gopalakrishnan V, Kasi PM, et al. Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma. Cancer. 2014;120:3902–3913.
   PubMed Web of Science ®Google Scholar
• Zhao J, Fan YX, Yang Y, et al. Identification of potential plasma biomarkers for esophageal squamous cell carcinoma by a proteomic method. Int J Clin Exp Pathol. 2015;8:1535–1544.
   PubMed Web of Science ®Google Scholar
• Li C, Xia G, Jianqing Z, et al. Serum differential protein identification of Xinjiang Kazakh esophageal cancer patients based on the two-dimensional liquid-phase chromatography and LTQ MS. Mol Biol Rep. 2014;41:2893–2905.
   PubMed Web of Science ®Google Scholar
• Wan QL, Hou XS, Zhao G. Utility of serum peptidome patterns of esophageal squamous cell carcinoma patients for comprehensive treatment. Asian Pac J Cancer Prev. 2013;14:2919–2923.
   PubMedGoogle Scholar
• Fan NJ, Gao CF, Wang XL. Tubulin beta chain, filamin A alpha isoform 1, and cytochrome b-c1 complex subunit 1 as serological diagnostic biomarkers of esophageal squamous cell carcinoma: a proteomics study. Omics. 2013;17:215–223.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Nakanishi T, Miyamoto Y, et al. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett. 2008;263:280–290.
   PubMed Web of Science ®Google Scholar
• Kim HK, Reyzer ML, Choi IJ, et al. Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res. 2010;9:4123–4130.
   PubMed Web of Science ®Google Scholar
• Subbannayya Y, Syed N, Barbhuiya MA, et al. Calcium calmodulin dependent kinase kinase 2 - a novel therapeutic target for gastric adenocarcinoma. Cancer Biol Ther. 2015;16:336–345.
   PubMed Web of Science ®Google Scholar
• Bai Z, Ye Y, Liang B, et al. Proteomics-based identification of a group of apoptosis-related proteins and biomarkers in gastric cancer. Int J Oncol. 2011;38:375–383.
   PubMed Web of Science ®Google Scholar
• Zhang ZQ, Li XJ, Liu GT, et al. Identification of annexin A1 protein expression in human gastric adenocarcinoma using proteomics and tissue microarray. World J Gastroenterol. 2013;19:7795–7803.
   PubMed Web of Science ®Google Scholar
• Sousa JF, Ham AJ, Whitwell C, et al. Proteomic profiling of paraffin-embedded samples identifies metaplasia-specific and early-stage gastric cancer biomarkers. Am J Pathol. 2012;181:1560–1572.
   PubMed Web of Science ®Google Scholar
• Balluff B, Rauser S, Meding S, et al. MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol. 2011;179:2720–2729.
   PubMed Web of Science ®Google Scholar
• Gao W, Xu J, Wang F, et al. Plasma membrane proteomic analysis of human gastric cancer tissues: revealing flotillin 1 as a marker for gastric cancer. BMC Cancer. 2015;15:367.
   PubMed Web of Science ®Google Scholar
• Morita Y, Ikegami K, Goto-Inoue N, et al. Imaging mass spectrometry of gastric carcinoma in formalin-fixed paraffin-embedded tissue microarray. Cancer Sci. 2010;101:267–273.
   PubMed Web of Science ®Google Scholar
• Cai Z, Zhao JS, Li JJ, et al. A combined proteomics and metabolomics profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism. Mol Cell Proteomics. 2010;9:2617–2628.
   PubMed Web of Science ®Google Scholar
• Liu WL, Zhang G, Wang JY, et al. Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2008;375:440–445.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang K, Zhang J, et al. Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res. 2011;10:2863–2872.
   PubMed Web of Science ®Google Scholar
• Liu Z, Feng JG, Tuersun A, et al. Proteomic identification of differentially-expressed proteins in esophageal cancer in three ethnic groups in Xinjiang. Mol Biol Rep. 2011;38:3261–3269.
   PubMed Web of Science ®Google Scholar
• Zhu X, Ding M, Yu ML, et al. Identification of galectin-7 as a potential biomarker for esophageal squamous cell carcinoma by proteomic analysis. BMC Cancer. 2010;10:290.
   PubMed Web of Science ®Google Scholar
• Uemura N, Nakanishi Y, Kato H, et al. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics. Int J Cancer. 2009;124:2106–2115.
   PubMed Web of Science ®Google Scholar
• Fan NJ, Gao CF, Wang CS, et al. Identification of the up-regulation of TP-alpha, collagen alpha-1(VI) chain, and S100A9 in esophageal squamous cell carcinoma by a proteomic method. J Proteomics. 2012;75:3977–3986.
   PubMed Web of Science ®Google Scholar
• Pawar H, Kashyap MK, Sahasrabuddhe NA, et al. Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. Cancer Biol Ther. 2011;12:510–522.
   PubMed Web of Science ®Google Scholar
• Uemura N, Nakanishi Y, Kato H, et al. Antibody-based proteomics for esophageal cancer: identification of proteins in the nuclear factor-κB pathway and mitotic checkpoint. Cancer Sci. 2009;100:1612–1622.
   PubMed Web of Science ®Google Scholar
• Niimi T, Nagashima K, Ward JM, et al. Claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol. 2001;21:7380–7390.
   PubMed Web of Science ®Google Scholar
• Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14:7624–7634.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–209.
   PubMed Web of Science ®Google Scholar
• Huang H, Han Y, Gao J, et al. High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients. Med Oncol. 2013;30:748.
   PubMed Web of Science ®Google Scholar
• Langer R, Ott K, Specht K, et al. Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response. Clin Cancer Res. 2008;14:8279–8287.
   PubMed Web of Science ®Google Scholar
• Kelly P, Paulin F, Lamont D, et al. Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Br J Cancer. 2012;106:955–961.
   PubMed Web of Science ®Google Scholar
• Maher SG, McDowell DT, Collins BC, et al. Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation. Ann Surg. 2011;254:809–816.
   PubMed Web of Science ®Google Scholar
• Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–4393.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–730.
   PubMed Web of Science ®Google Scholar
• Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–1396.
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–1820.
   PubMed Web of Science ®Google Scholar
• Helgason HH, Engwegen JY, Zapatka M, et al. Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer. Oncol Lett. 2010;1:327–333.
   PubMed Web of Science ®Google Scholar
• Yu Z, Yu JK, Fang XF, et al. Proteomic biomarker predicts therapeutical effects of oxaliplatin combining with fluoropyrimidine in metastatic gastric cancer patients by the SELDI-proteinchip platform. Hepatogastroenterology. 2013;60:1800–1804.
   PubMed Web of Science ®Google Scholar
• Qian J, Li F, Yu J, et al. Mining predictive biomarker for neoadjuvant chemotherapy in gastric cancer by proteomics. Hepatogastroenterology. 2011;58:1828–1833.
   PubMed Web of Science ®Google Scholar
• Obuchi W, Ohtsuki S, Uchida Y, et al. Identification of transporters associated with etoposide sensitivity of stomach cancer cell lines and methotrexate sensitivity of breast cancer cell lines by quantitative targeted absolute proteomics. Mol Pharmacol. 2013;83:490–500.
   PubMed Web of Science ®Google Scholar
• Hu HD, Ye F, Zhang DZ, et al. iTRAQ quantitative analysis of multidrug resistance mechanisms in human gastric cancer cells. J Biomed Biotechnol. 2010;2010:571343.
   PubMedGoogle Scholar
• Rice TW, Rusch VW, Apperson-Hansen C, et al. Worldwide esophageal cancer collaboration. Dis Esophagus. 2009;22:1–8.
   PubMed Web of Science ®Google Scholar
• Van Hagen P, Hulshof MCCM, Van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–2084.
   PubMed Web of Science ®Google Scholar
• Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281:1623–1627.
   PubMed Web of Science ®Google Scholar
• Kelly P, Appleyard V, Murray K, et al. Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. Br J Cancer. 2010;103:232–238.
   PubMed Web of Science ®Google Scholar
• Liu JS, He SC, Zhang ZL, et al. Anticancer effects of β-elemene in gastric cancer cells and its potential underlying proteins: a proteomic study. Oncol Rep. 2014;32:2635–2647.
   PubMed Web of Science ®Google Scholar
• Morisaki T, Yashiro M, Kakehashi A, et al. Comparative proteomics analysis of gastric cancer stem cells. PLoS One. 2014;9:e110736.
   PubMed Web of Science ®Google Scholar
• Li K, Sun Z, Zheng J, et al. In-depth research of multidrug resistance related cell surface glycoproteome in gastric cancer. J Proteomics. 2013;82:130–140.
   PubMed Web of Science ®Google Scholar
• Hu CW, Tseng CW, Chien CW, et al. Quantitative proteomics reveals diverse roles of miR-148a from gastric cancer progression to neurological development. J Proteome Res. 2013;12:3993–4004.
   PubMed Web of Science ®Google Scholar
• Syed N, Barbhuiya MA, Pinto SM, et al. Phosphotyrosine profiling identifies ephrin receptor A2 as a potential therapeutic target in esophageal squamous-cell carcinoma. Proteomics. 2015;15:374–382.
   PubMed Web of Science ®Google Scholar
• Chen HB, Pan K, Tang MK, et al. Comparative proteomic analysis reveals differentially expressed proteins regulated by a potential tumor promoter, BRE, in human esophageal carcinoma cells. Biochem Cell Biol. 2006;86:302–311.
   Web of Science ®Google Scholar
• Kashyap MK, Harsha HC, Renuse S, et al. SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. Cancer Biol Ther. 2010;10:796–810.
   PubMed Web of Science ®Google Scholar
• Wen J, Zheng B, Hu Y, et al. Comparative proteomic analysis of the esophageal squamous carcinoma cell line EC109 and its multi-drug resistant subline EC109/CDDP. Int J Oncol. 2010;36:265–274.
   PubMed Web of Science ®Google Scholar
• Yan GR, Xu SH, Tan ZL, et al. Proteomics characterization of gastrokine 1-induced growth inhibition of gastric cancer cells. Proteomics. 2011;11:3657–3664.
   PubMed Web of Science ®Google Scholar
• He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522–531.
   PubMed Web of Science ®Google Scholar
• Ishimoto T, Baba H, Izumi D, et al. Current perspectives toward the identification of key players in gastric cancer microRNA dysregulation. Int J Cancer. 2016;138:1337–1349.
   PubMed Web of Science ®Google Scholar
• Zhang K, Li L, Zhu M, et al. Comparative analysis of histone H3 and H4 post-translational modifications of esophageal squamous cell carcinoma with different invasive capabilities. J Proteomics. 2015;112:180–189.
   PubMed Web of Science ®Google Scholar
• Kam SY, Hennessy T, Chua SC, et al. Characterization of the human gastric fluid proteome reveals distinct pH-dependent protein profiles: implications for biomarker studies. J Proteome Res. 2011;10:4535–4546.
   PubMed Web of Science ®Google Scholar
• Kon OL, Yip TT, Ho MF, et al. The distinctive gastric fluid proteome in gastric cancer reveals a multi-biomarker diagnostic profile. BMC Med Genomics. 2008;1:54.
   PubMed Web of Science ®Google Scholar
• Hsu PI, Chen CH, Hsieh CS, et al. α-Antitrypsin precursor in gastric juice is a novel biomarker for gastric cancer and ulcer. Clin Cancer Res. 2007;13:876–883.
   PubMed Web of Science ®Google Scholar
• Husi H, Skipworth RJ, Cronshaw A, et al. Programmed cell death 6 interacting protein (PDCD6IP) and Rabenosyn-5 (ZFYVE20) are potential urinary biomarkers for upper gastrointestinal cancer. Proteomics Clin Appl. 2015;9:586–596.
   PubMed Web of Science ®Google Scholar
• Paulo JA, Lee LS, Wu B, et al. Proteomic analysis of endoscopically (endoscopic pancreatic function test) collected gastroduodenal fluid using in-gel tryptic digestion followed by LC-MS/MS. Proteomics Clin Appl. 2010;4:715–725.
   PubMed Web of Science ®Google Scholar
• Kentsis A, Monigatti F, Dorff K, et al. Urine proteomics for profiling of human disease using high accuracy mass spectrometry. Proteomics Clin Appl. 2009;3:1052–1061.
   PubMed Web of Science ®Google Scholar
• Haraldsson B, Sorensson J. Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. News Physiol Sci. 2004;19:7–10.
   PubMedGoogle Scholar
• Adachi J, Kumar C, Zhang Y, et al. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 2006;7:R80.
   PubMed Web of Science ®Google Scholar
• Martinez E, Marcos A. Helicobacter pylori and peptic ulcer disease. N Engl J Med. 1991;325:737–738.
   PubMed Web of Science ®Google Scholar
• Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–1131.
   PubMed Web of Science ®Google Scholar
• Lian G, Wei C, Wang D, et al. Protein profiling of Helicobacter pylori-associated gastric cancer. Am J Pathol. 2014;184:1343–1354.
   PubMed Web of Science ®Google Scholar
• Momynaliev KT, Kashin SV, Chelysheva VV, et al. Functional divergence of Helicobacter pylori related to early gastric cancer. J Proteome Res. 2010;9:254–267.
   PubMed Web of Science ®Google Scholar
• Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218:583–592.
   PubMed Web of Science ®Google Scholar
• Carter D, Trede M, Beger HG, et al. Does saving the pylorus in pancreatoduodenectomy for periampullary cancer have a value? Langenbecks Arch Chir. 1994;379:58–63.
   PubMedGoogle Scholar
• Honda K, Kobayashi M, Okusaka T, et al. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Sci Rep. 2015;5:15921.
   PubMed Web of Science ®Google Scholar